Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Continued Access to PREVAIL (CAP2)- WATCHMAN Left Atrial Appendage (LAA) Closure Technology

NCT01760291 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT01760291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01760291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Continued Access to PREVAIL (CAP2)- WATCHMAN Left Atrial Appendage (LAA) Closure Technology
Lead sponsor
Boston Scientific Corporation
Phase
Not applicable
Overall status
Completed
Start date
September 30, 2012
Completion date
April 30, 2019
Enrollment
576 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation